whether the HRCT features could discriminate between the antibody-positive and 1 negative cases. The study population included all patients who were diagnosed with DM at 6 Kyoto University Hospital between 2005 and 2009. DM was diagnosed using the Bohan 7
and Peter criteria. 8 C-ADM was diagnosed if a patient had the characteristic skin rash of 8 DM but little or no muscle symptoms and serum creatine kinase (CK) was <300 IU/L 9 during the study period, as described previously. 5, 6 We excluded patients who had active 10 neoplasm or other connective tissue disease (CTD), or had been treated with systemic 11 corticosteroid (CS) or immunosuppressive agents before referral to our hospital. Among 12 the remaining 32 patients, ILD was confirmed in 25 (78.1%) based on HRCT. Acute and 13 subacute DM-ILD subtypes were diagnosed when respiratory failure developed within 1 14 month and within 1 to 3 months, respectively, from the onset of symptoms or the 15 initiation of treatment. 16
All patients provided written informed consent before blood sample collection. 17
The Kyoto University Hospital Institutional Review Board approved this retrospective 18 study. 19
20
Clinical evaluation 21
Clinical information was retrospectively collected from medical records. All 22 patients were evaluated by at least two rheumatologists prior to treatment and had blood 1 tests at their first visit. Most patients also underwent standardized pulmonary function 2 tests, 9 and arterial blood gas analysis was done before treatment. Published equations 3
for Japanese adults were used to determine predicted values of each parameter. 10 4 5
Measurement of MSAs 6
Serum samples were obtained from all patients at the first visit prior to receiving 7 immunosuppressive therapies. The presence of MSAs was determined by RNA-8 immunoprecipitation (RNA-IPP) for anti-ARS and protein-immunoprecipitation (P-IPP) 9
for anti-CADM-140 as described previously. 6 Patients were divided into two groups 10 based on the presence or absence of anti-CADM-140: anti-CADM-140 (+) or (-), 11
respectively. 12
13
HRCT scanning protocol 14
Thin-section CT images were obtained with a multi-detector CT scanner 15 (Aquilion 64; Toshiba Medical Systems, Tochigi, Japan). Whole lung scans 16
were performed at peak tube voltage of 120 kVp with variable mAs setting using an 17 automatic exposure control system (SD value 8.5). Contiguous 7-mm-thick images and 18 HRCT images (2 mm) were prepared for review. 19
20

HRCT evaluation 21
All patients underwent chest HRCT prior to treatment, and images were 22 reviewed by three independent observers (T.K., T.H., and K.T. with 15, 12, and 10 years 1 of experience, respectively) blinded to clinical information. Inter-observer 2 disagreements were resolved by consensus. 3
Images were assessed for the presence of ground-glass attenuation (GGA), 4 consolidation, intralobular reticular opacities, interlobular septal thickening, non-septal 5 linear or plate-like opacity, substantial micronodules, honeycombing, emphysema, 6 traction bronchiectasis, and lobar volume loss. The presence of mediastinal lymph node 7 enlargement or pleural effusion and the laterality of abnormalities were also assessed. 8
HRCT findings were interpreted according to the recommendations of the 9
Nomenclature Committee of the Fleischner Society. 11 Nonseptal linear or plate-like 10 opacity was defined as an elongated line of soft tissue attenuation that was distinct from 11 interlobular septa and bronchovascular bundles, including subpleural curvilinear lines 12 and subpleural bands. 12 
13
Through reviewing all HRCT images, we found that all 25 cases could be 14 categorized into a few HRCT patterns, based on dominant CT findings, and the 15 craniocaudal and axial distribution of these findings. The dominant findings were 16 classified as GGA, consolidation, or reticulation (intralobular reticular opacities, 17 interlobular septal thickening, or nonseptal linear or plate-like opacity). The 18 craniocaudal distribution was assessed as upper, lower, diffuse, or random. Upper 19 distribution was defined as extensive findings predominantly above the level of inferior 20 pulmonary veins, lower when there were more below this level, diffuse when 21 generalized, and random for no zonal predominance. The axial distribution was 22 classified as peribronchovascular when the dominant findings were along the bronchi 1 and vessels, peripheral when in the outer one-third of the lung, diffuse when generalized, 2 or random when no distribution pattern was apparent. 3 4
Statistical analysis 5
Statistical analysis was performed using JMP ® version 6 (SAS Institute Inc. 6
Cary, NC, USA). All statistical variations in quantitative data were expressed as a single 7 determination standard deviation, and a P value less than 0.05 was considered to 8 indicate statistical significance. 9
Group comparisons were made using Fisher's exact test, χ 2 test, and 10
Mann-Whitney U test. Cumulative survival probabilities were estimated using the 11
Kaplan-Meier method and the log-rank test. 12
13
Results 14
Initial clinical features 15
Demographics, clinical manifestations and laboratory test results of patients in 16
the anti-CADM-140 (+) and (-) groups are summarized in Table 1 . The prevalence of 17 C-ADM showed no significant difference (50.0% vs. 30.8%, P = 0.43). Acute DM-ILD 18 was diagnosed in 25% of patients in the anti-CADM-140 (+), and 0% of patients in the 19 anti-CADM-140 (-) group (P = 0.10), while the sum of acute and subacute subtypes was 20 41.7% and 7.7%, respectively (P = 0.07). Before treatment, white blood cells, platelets, 21 CK, and aldolase levels were lower in the anti-CADM-140 (+) group. Pretreatment 22 ferritin and its maximal value were both higher in the anti-CADM-140 (+) group. In the 1 anti-CADM-140 (-) group, 10 patients (76.9%) were positive for anti-ARS: three with 2 EJ, three with PL-7, two with Jo-1, one with OJ, and one with PL-12. Arterial blood gas 3 analyses and pulmonary functional tests revealed no significant differences (data not 4 shown). No patients underwent surgical lung biopsy (SLB) in either group. HRCT findings are shown in Table 2 . Common findings were GGA (83.3%), 8 nonseptal linear or plate-like opacity (83.3%), and interlobular septal thickening 9 (66.7%) in the anti-CADM-140 (+) group; and GGA (100.0%), intralobular reticular 10 opacities (84.6%), non-septal linear or plate-like opacity (53.8%), and lobular volume 11 loss (53.8%) in the anti-CADM-140 (-) group. Among the HRCT findings, intralobular 12 reticular opacities were significantly different between the groups (0% in 13 anti-CADM-140 (+) vs. 84.6% in anti-CADM-140 (-), P < 0.0001). 14 Next, we categorized all 25 cases into four HRCT patterns: lower 15 consolidation/GGA pattern (lower peripheral or peribronchovascular consolidations or 16 GGA); lower reticulation pattern (lower peripheral or peribronchovascular reticulation); 17 random GGA pattern (random peripheral GGA); and others. Lower consolidation/GGA 18 pattern was characterized by nonsegmental consolidations or GGA, with subpleural or 19 peribronchovascular distribution (Figs. 1 and 2). Lower reticulation pattern showed a 20 homogeneous distribution with some subpleural sparing ( Fig. 3 ). In random GGA 21 pattern, small GGAs were seen in a patchy manner in the absence of consolidation ( Fig.  22 
4). 1
The HRCT patterns were significantly different between the anti-CADM-140 2 (+) and (-) groups (P = 0.002): with lower consolidation/GGA pattern (50.0%) and 3 random GGA pattern (33.3%) in the anti-CADM-140 (+) group, and lower reticulation 4 pattern (69.2%) in the anti-CADM-140 (-) group. Additionally, the dominant 5 abnormalities were seen in lower lung fields (6/12, 50%) or randomly (4/12, 33.3%) in 6 anti-CADM-140-positive patients, compared to lower lung fields (12/13, 93.2%) in 7 most anti-CADM-140-negative patients (P = 0.04). The HRCT patterns in the seven 8 fatal anti-CADM-140 (+) cases were lower consolidation/GGA pattern in four, random 9
GGA pattern in two (including the one patient who died of Pneumocystis jiveroci 10 pneumonia and sepsis), and others in one (Table 3 ). Of 10 patients with anti-ARS 11 antibodies in the anti-CADM-140 (-) group, six (60.0%) had a lower reticulation pattern 12 and two (20.0%) had lower consolidation/GGA pattern. Three patients who were 13 negative for both anti-CADM-140 and anti-ARS showed lower reticulation pattern. anti-CADM-140 (-) group. Lower reticulation pattern is consistent with idiopathic 20 nonspecific interstitial pneumonia (NSIP) 13-15 and DM/PM-ILD having biopsy-proven 21 NSIP pattern: 16 reticulation, GGAs, lobar volume loss, and lower predominance, but 22 little or no honeycombing. More than half of the anti-CADM-140-negative patients 1 (69.2%, including six anti-ARS positive patients) in our series had this pattern, 2 suggestive of pathological NSIP pattern. On the other hand, lower consolidation/GGA 3 and random GGA patterns are more difficult to interpret. Lower consolidation/GGA 4 pattern may indicate organized pneumonia (OP) 14 17 or localized diffuse alveolar 5 damage (DAD). 14 17-19 The mortality in patients with this pattern was as high as 50.0% 6 (4/8), suggesting a high prevalence of DAD although radiopathological correlation was showed OP pattern in most cases. 20 In random GGA pattern, most lesions were too 10 small to speculate pathology. 11
Another significant characteristic of anti-CADM-140-positive DM-ILD was the 12 absence of intralobular reticular opacities. Intralobular reticular opacities represent 13 abnormal thickening of intralobular interstitial tissue 11 and were observed in 87% of 14 idiopathic NSIP patients 13 and 92% of DM/PM-ILD patients with biopsy-proven NSIP 15 pattern. 16 Thus, the absence of lower reticulation pattern and intralobular reticular 16 outcomes of DM/PM-ILD patients with biopsy-proven NSIP pattern were much better 20 than those of our anti-CADM-140-positive patients. 16 Although the prognostic value of 21 pathology in DM-ILD have not been established, these differences in both radiological 22
findings and survival suggest that the anti-CADM-140 (+) group includes patients 1 distinct from those with pathological NSIP. 2
On the other hand, HRCT findings other than intralobular reticular opacities 3
were not significantly different between the anti-CADM-140 (+) and (-) groups. Our 4 results indicate that HRCT patterns may be more helpful in discriminating between 5
anti-CADM-140-positive and negative cases than several nonspecific findings. The 6
HRCT patterns in our study were based on the major abnormalities and the distributions 7 of those abnormalities to describe the overall picture comprehensively and concisely. 8
Thus, the complete picture of HRCT images, rather than the presence of individual 9
abnormalities probably characterized anti-CADM-140-positive cases better. 10
Among MSAs, anti-ARS has also been reported to be associated with ILD in 11 DM/PM patients. 21 Of 13 anti-CADM-140 negative cases in our study, 10 were positive 12 for anti-ARS, and the HRCT patterns were similar between anti-ARS-positive and 13 negative cases: lower reticulation pattern was predominant (60.0% and 40.0% in 14
anti-ARS-positive and negative patients, respectively). These findings indicate that 15 anti-CADM-140 may be more influential on the HRCT patterns of DM-ILD than 16
anti-ARS. 17
Notably, the prevalence of C-ADM was not significantly different 18 between anti-CADM-140 (+) and (-) groups. In spite of the designation, half the patients 19
in the anti-CADM-140 (+) group did not fulfill the criteria for C-ADM. Such a 20 discrepancy between anti-CADM-140 and C-ADM was also suggested by Gono and 21 coworkers. 7 In addition, the results of pulmonary function tests and arterial gas analyses 22 at diagnosis were not significantly different. These findings indicate that, while this 1 antibody is a strong predictor of mortality, the initial clinical data cannot necessarily 2 discriminate between anti-CADM-140-positive and negative cases in DM-ILD. In 3 contrast, the HRCT features were significantly different between the two groups, 4
suggesting the clinical utility of HRCT evaluation for predicting the presence of helpful in these analyses. 20
We should mention some limitations of this study. First, this study was a 21 small-sized study in a single center. Second, serial changes in HRCT images were not 22 addressed because follow-up HRCT was performed at rather arbitrary intervals. The 1 effects of treatment on HRCT features and their prognostic values should be further 2 studied in a prospective design. Third, radiopathological correlation was not confirmed. Fourth, anti-CADM-140 has been reported exclusively in Japanese patients thus far. 5-7 7 To establish the clinical relevance of this antibody, further studies in other ethnic 8 populations are required. 9
Despite these limitations, we demonstrated that lower consolidation/GGA 10 pattern and random GGA patterns as well as the absence of intralobular reticular 11 
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